[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659050":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":13,"armGroups":20,"interventions":31,"overallOfficials":13,"centralContacts":40,"locations":46,"responsibleParty":193,"collaborators":13,"id":195,"slug":196,"hasResults":197,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":13,"eligibilityCriteria":201,"healthyVolunteers":197,"sex":202,"minAge":203,"maxAge":204,"enrollmentInfo":205,"targetDuration":13,"studyType":208,"phases":209,"briefSummary":211,"conditions":212,"keywords":13,"overallStatus":49,"whyStopped":13,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":223},{"fullName":5,"class":6},"magAssist, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"30-day MAE rate after randomization","The major adverse events are defined as:\n\nDeath. Stroke. Myocardial infarction. Revascularization. Rehospitalization due to cardiovascular reasons. Type 3, 4, and 5 bleeding (as defined by MCS-ARC). Acute kidney injury. Severe device-related adverse events. Cardiopulmonary resuscitation.","30-day after randomization",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE",[21,26],{"label":22,"type":23,"description":13,"interventionNames":24},"NyokAssist™","EXPERIMENTAL",[25],"Device: NyokAssist",{"label":27,"type":28,"description":13,"interventionNames":29},"ECMO","ACTIVE_COMPARATOR",[30],"Device: ECMO",[32,37],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":13},"DEVICE","NyokAssist","The NyokAssist™ Ventricular Assist Device can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta .",[22],{"type":33,"name":27,"description":38,"armGroupLabels":39,"otherNames":13},"Extracorporeal Membrane Oxygenation provides extracorporeal gas exchange through use of a membrane oxygenator. Blood is drained from a central vein and returned after oxygenation into the arterial circulation .",[27],[41],{"name":42,"role":43,"phone":44,"phoneExt":13,"email":45},"YE","CONTACT","+86-18662176199","beibei.ye@magassist.tech",[47,62,73,84,92,100,111,122,133,144,155,163,174,185],{"facility":48,"status":49,"city":50,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Luhe Hospital, Capital Medical University","RECRUITING","Beijing","China","CN",{"type":54,"coordinates":55},"Point",[56,57],116.39723,39.9075,{"lat":57,"lon":56},[60],{"name":61,"role":43,"phone":13,"phoneExt":13,"email":13},"Zhai Guangyao",{"facility":63,"status":49,"city":64,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"The Second Xiangya Hospital of Central South University","Changsha",{"type":54,"coordinates":66},[67,68],112.97087,28.19874,{"lat":68,"lon":67},[71],{"name":72,"role":43,"phone":13,"phoneExt":13,"email":13},"Fang Zhenfei",{"facility":74,"status":49,"city":75,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Guangdong Provincial People's Hospital","Guangzhou",{"type":54,"coordinates":77},[78,79],113.25,23.11667,{"lat":79,"lon":78},[82],{"name":83,"role":43,"phone":13,"phoneExt":13,"email":13},"Jing Zhicheng",{"facility":85,"status":49,"city":75,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":86,"geoPoint":88,"contacts":89},"Nanfang Hospital Southern Medical University",{"type":54,"coordinates":87},[78,79],{"lat":79,"lon":78},[90],{"name":91,"role":43,"phone":13,"phoneExt":13,"email":13},"Xiu Jiancheng",{"facility":93,"status":49,"city":75,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":94,"geoPoint":96,"contacts":97},"The First Affiliated Hospital of Jinan University",{"type":54,"coordinates":95},[78,79],{"lat":79,"lon":78},[98],{"name":99,"role":43,"phone":13,"phoneExt":13,"email":13},"Guo Jun",{"facility":101,"status":49,"city":102,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"The Second Affiliated Hospital of Nanchang University","Nanchang",{"type":54,"coordinates":104},[105,106],115.85306,28.68396,{"lat":106,"lon":105},[109],{"name":110,"role":43,"phone":13,"phoneExt":13,"email":13},"Yang Renqiang",{"facility":112,"status":49,"city":113,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"ZhongShan Hospital Fudan University","Shanghai",{"type":54,"coordinates":115},[116,117],121.45806,31.22222,{"lat":117,"lon":116},[120],{"name":121,"role":43,"phone":13,"phoneExt":13,"email":13},"Ge Junbo",{"facility":123,"status":49,"city":124,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":125,"geoPoint":129,"contacts":130},"The First Hospital of China Medical University","Shenyang",{"type":54,"coordinates":126},[127,128],123.43278,41.79222,{"lat":128,"lon":127},[131],{"name":132,"role":43,"phone":13,"phoneExt":13,"email":13},"Sun Yingxian",{"facility":134,"status":49,"city":135,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"The Second Affiliated Hospital of Soochow University","Suzhou",{"type":54,"coordinates":137},[138,139],120.59538,31.30408,{"lat":139,"lon":138},[142],{"name":143,"role":43,"phone":13,"phoneExt":13,"email":13},"Li Hun",{"facility":145,"status":49,"city":146,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Tangdu Hospital of Air Force Military Medical University","Xi'an",{"type":54,"coordinates":148},[149,150],108.92861,34.25833,{"lat":150,"lon":149},[153],{"name":154,"role":43,"phone":13,"phoneExt":13,"email":13},"Li Yan",{"facility":156,"status":49,"city":146,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":157,"geoPoint":159,"contacts":160},"The First Affiliated Hospital of Xi'an Jiaotong University",{"type":54,"coordinates":158},[149,150],{"lat":150,"lon":149},[161],{"name":162,"role":43,"phone":13,"phoneExt":13,"email":13},"Yuan Zuyi",{"facility":164,"status":49,"city":165,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Xiamen Cardiovascular Hospital Xiamen University","Xiamen",{"type":54,"coordinates":167},[168,169],118.08187,24.47979,{"lat":169,"lon":168},[172],{"name":173,"role":43,"phone":13,"phoneExt":13,"email":13},"Wang Yan",{"facility":175,"status":49,"city":176,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":177,"geoPoint":181,"contacts":182},"Fu Wai Central China Cardiovascular Hospital","Zhengzhou",{"type":54,"coordinates":178},[179,180],113.64861,34.75778,{"lat":180,"lon":179},[183],{"name":184,"role":43,"phone":13,"phoneExt":13,"email":13},"Ye Faming",{"facility":186,"status":49,"city":176,"state":13,"zip":13,"country":51,"countryCode":52,"cosmosGeoPoint":187,"geoPoint":189,"contacts":190},"The 7th People's Hospital of Zhengzhou",{"type":54,"coordinates":188},[179,180],{"lat":180,"lon":179},[191],{"name":192,"role":43,"phone":13,"phoneExt":13,"email":13},"Li Jing",{"type":194,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100659050","save-pci--nyokassist-small-bore-vad-vs-ecmo-in-elective-high-risk-pci-100659050",false,"NCT07860671","SAVE-PCI Ⅱ: NyokAssist™ Small-Bore VAD vs. ECMO in Elective High-Risk PCI","A Prospective, Multi-center, Randomized Controlled, Non-Inferiority Trial to Evaluate the Safety and Efficacy of a Percutaneous Ventricular Assist Device","Inclusion Criteria:\n\n1\\. Age eligible (18 ≤ Age ≤ 90). 2. Subject is indicated for a non-emergent percutaneous treatment of at least one de novo or restenotic lesion in a native coronary vessel or bypass graft .\n\n3\\. The subjects' left ventricular ejection fraction (LVEF) and imaging results met both of the following a and b :\n\n1. LVEF ≤ 35%; or LVEF ≤ 40% with NYHA functional class ≥ III.\n2. Imaging criteria:\n\n   Chronic total occlusion (CTO) in at least two vessels; or No unprotected left main coronary artery lesion; or Three-vessel disease.\n\n   \\*Three-vessel disease was defined as the presence at least one sign ficant stenosis ≥ 50% in the left anterior descending artery (LAD) and\u002For side branch, left circumflex artery (LCX) and\u002For side branch, and right coronary artery (RCA) and\u002For side branch. In the case of left coronary artery dominance, a lesion ≥ 50% in the proximal LAD and the LCX qualified as three-vessel disease.\n\n   5.Volunteered to participate and Signed Informed Consent and able to cooperate with the whole trial process.\n\n   Exclusion Criteria:\n\n   1.Acute ST elevation Myocardial Infarction within 24 hours or CK-MB that have not normalized after acute ST elevation Myocardial Infarction.\n\n   2.Pre-procedure cardiac arrest within 24 hours of enrollment requiring CPR. 3.Subject is in cardiogenic shock defined as:\n   * CI \\\u003C 2.2 L\u002Fmin\u002Fm2 and PCWP \\> 15 mmH\n   * Hypotension (systolic BP \\\u003C 90 mmHg for \\>30 minutes or the need for supportive measures to maintain a systolic BP of greater than or equal to 90 mmHg) AND end organ hypoperfusion (cool extremities OR \\[a urine output of \\\u003C 30 mL\u002Fhour AND a HR \\> 60 BPM\\]) 4.Mural thrombus in the left ventricle. 5.The presence of aortic valve replacement or mechanical circulatory support device. 6.Subject has mechanical complications of myocardial infarction.\n\n     7.Documented presence of severe aortic stenosis. aortic valve area (AVA) ≤ 1.0 cm².\n\n     8.Documented presence of moderate to severe mitral stenosis. 9.Documented presence of moderate to severe aortic insufficiency. 10.Severe peripheral arterial obstructive disease that would preclude device placement.\n\n     11.Abnormalities of the aorta that would preclude surgery, including aortic aneurysms,aortic dissection and extreme tortuosity or calcifications.\n\n     12.Subject with renal failure (creatinine ≥265μmol\u002FL) . 13.Subject with liver dysfunction ( liver enzymes and bilirubin levels ≥3x URL or INR≥2 ).\n\n     14.Subject has uncorrectable abnormal coagulation parameters (platelet count ≤ 75╳109 \u002FL or fibrinogen ≤ 1.50 g\u002FL or INR≥2) .\n\n     15.History of recent (within 1 month) stroke or TIA . 16.Severe right ventricular dysfunction,such as severe pulmonary hypertension. 17.Allergy or intolerance to heparin, aspirin, ADP receptor inhibitors or contrast media.\n\n     18.Subject with documented heparin induced thrombocytopenia. 19.Atrial or ventricular septal defect (including post-infarction ventricular septal rupture).\n\n     20.Subject has pregnant or lactating. 21.Participation in the active follow-up phase of another clinical study of an investigational drug or device within 1 month.\n\n     22.Investigators consider unsuitable to participate in the trial.","ALL","18 Years","90 Years",{"count":206,"type":207},204,"ESTIMATED","INTERVENTIONAL",[210],"NA","SAVE-PCI Ⅱ is a prospective, multi-center, randomized controlled trial evaluating the safety and efficacy of NyokAssist™, a small-bore percutaneous ventricular assist device (pVAD), in comparison with ECMO in patients undergoing elective high-risk percutaneous coronary intervention (PCI).",[213],"High-risk PCI","2026-09-30",{"date":216,"type":217},"2026-10-06","ACTUAL",{"date":219,"type":217},"2026-04-09",{"date":221,"type":207},"2027-03-31",{"name":5,"class":6},14]